Epigenetic targets of Janus kinase inhibitors are linked to genetic risks of rheumatoid arthritis.

JAKis and the TNFi had a direct impact on different RA risk enhancers, and we identified nucleotide-resolution targets for both drugs. Distinctive targets of clinically effective drugs could be useful for tailoring the application of these drugs and future design of more efficient treatment strategies.